国际医药卫生导报2016，Vol.22Issue(15)：2320-2322,3.DOI:10.3760/cma.j.issn.1007-1245.2016.15.036
培美曲塞二钠联合卡铂治疗老年中晚期非小细胞肺癌的临床探讨
Clinical discussion on elderly patients with middle-late stage non-small cell lung cancer treated with pemetrexed disodium and carboplatin
闫俊丽 1贺会江 1李向平1
作者信息
- 1. 471000 洛阳,中国人民解放军第150中心医院
- 折叠
摘要
Abstract
Objective To study the clinical effect on elderly patients with middle-late stage non-small cell lung cancer treated with pemetrexed disodium and carboplatin.Methods From September 2012 to December 2014,100 elderly patients with middle-late stage non-small cell lung cancer were collected and randomly divided into observation group and control group with 50 cases in each group.Observation group was treated with pemetrexed disodium and carboplatin,while control group was treated with gemcitabine and carboplatin.Results The total effective rate of observation group was 56％,that of control group was 50％,without statistically significant difference (P＞0.05).After treatment,a total of 9 patients of observation group had adverse reactions of hematologic toxicity,5 patients had adverse reactions of digestive tract toxicity,3 patients had adverse reactions of biochemical toxicity,and 4 patients had other adverse reactions,all significantly less than those of control group (P＜0.05).The time of tumor progression (TTP) of observation group was (6.9±1.1) months,the median survival time (MST) was (8.6±1.3) months,and 1 year survival rate was 52.6％,with statistically significant differences compared with control group (P＜0.05).Conclusion Elderly patients with middle-late stage non-small cell lung cancer treated with pemetrexed disodium and carboplatin have fewer adverse reactions and longer survival time.关键词
培美曲塞二钠/卡铂/非小细胞肺癌Key words
Pemetrexed disodium/Carboplatin/Non-small cell lung cancer引用本文复制引用
闫俊丽,贺会江,李向平..培美曲塞二钠联合卡铂治疗老年中晚期非小细胞肺癌的临床探讨[J].国际医药卫生导报,2016,22(15):2320-2322,3.
